Medeva beefs up France and US with pounds 258m buy
Friday 07 June 1996
The US assets were acquired by RPR when it took over Fisons last year and include the group's former US headquarters at Rochester in New York State. They were spotted by Medeva as under-exploited during its abortive merger talks with Fisons.
The deal is being part-financed through a pounds 109m placing, with existing shareholders being offered the new shares on a one-for-six basis at 220p. The move was well received by analysts, who said it would be earnings- enhancing. Shares in Medeva jumped 30p to 261p.
Bill Bogie, chief executive, described the two acquisitions as "Medeva's most significant step forward in terms of both its operations and its potential to deliver earnings growth for shareholders". He said the deal took the group's strategy on several stages.
It gave them critical mass in France and the US. In the former, Dr Bogie said the acquisition of rights to respiratory, dermatological and non- prescription drugs would allow Medeva to cover the cost of the existing sales force, the marketing spend that goes with it and help to support new product launches.
The deals also give the group Fisons' pennkinetic slow release technology, which can be applied to products within Medeva's development pipeline, such as its Hepagene hepatitis vaccine and anaesthetics acquired last year. That would help turn the group into a fully-fledged pharmaceutical company into the next century, Dr Bogie said.
But he described the 10 products being acquired with the Rochester business as "a classic Medeva opportunity". In the six years of its life, the company had been good at generating and re-generating growth in the products its owns, he said, and the Rochester products had not had the support they required to generate growth.
The main drug being acquired is Tussionex, a treatment for heavy coughs, which generated $31.5m of the $99.7m sales produced in total by the US products last year. Delsym, a slow-release cough treatment for children, Pediapred, a steroid for treating a range of allergic to inflammatory conditions, Zaroxolyn, for heart and kidney failure, and Ionamin, an appetite suppressant, are also coming aboard in the deal.
Operating profits from the US drugs have grown from $36.3m to $54.4m in the last three years.
- 1 Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
- 2 Disney heiress Abigail disowns her share of family profits in West Bank company
- 3 Israel's propaganda machine is finally starting to misfire
- 4 Zayn Malik on Israel-Gaza: One Direction singer bombarded with Twitter death threats after posting #FreePalestine
- 5 'Hello mum, this is going to be hard for you to read ...'
Sally Farmiloe dead: Howards' Way actress, and former mistress of Jeffrey Archer, dies aged 60
Women in Turkey have a laugh in public at the deputy Prime Minister's expense
Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
Disney heiress Abigail disowns her share of family profits in West Bank company
Australian model Robyn Lawley stages naked protest against huge coal mine seven times the size of Sydney Harbour
The secret report that helps Israel hide facts
Land for gas: Merkel and Putin discussed secret deal could end Ukraine crisis
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
A day in the life of Vladimir Putin: The dictator in his labyrinth
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
- < Previous
- Next >
iJobs Money & Business
£20000 - £24000 per annum: Harrington Starr: A leading provider of web based m...
£28000 - £32000 per annum: Ashdown Group: Secretary (Sales Team Support) - Mat...
Competitive (DOE): Guru Careers: We are looking for an Assistant Management Ac...
£600 - £700 per day + competitive: Orgtel: Senior Investment Accounting Change...